Arch Biopartners Inc (ARCH) - Total Liabilities
Based on the latest financial reports, Arch Biopartners Inc (ARCH) has total liabilities worth CA$3.99 Million CAD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Arch Biopartners Inc - Total Liabilities Trend (1997–2025)
This chart illustrates how Arch Biopartners Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Arch Biopartners Inc Competitors by Total Liabilities
The table below lists competitors of Arch Biopartners Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
B&M European Value Retail SA
LSE:BME
|
UK | GBX3.30 Billion |
|
CLPS INC. DL-0001
F:1UK
|
Germany | €56.23 Million |
|
SUSTAINABLE POWER CL.A
F:9QE
|
Germany | €33.36 Million |
|
Lleidanetworks Serveis Telematics SA
MC:LLN
|
Spain | €11.70 Million |
|
Konsortium Transnasional Bhd
KLSE:4847
|
Malaysia | RM191.01 Million |
|
Isofol Medical AB
ST:ISOFOL
|
Sweden | Skr21.52 Million |
|
Japan Gold Corp
V:JG
|
Canada | CA$486.71K |
Liability Composition Analysis (1997–2025)
This chart breaks down Arch Biopartners Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.03 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 38.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Arch Biopartners Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Arch Biopartners Inc (1997–2025)
The table below shows the annual total liabilities of Arch Biopartners Inc from 1997 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-09-30 | CA$3.99 Million | -24.55% |
| 2024-09-30 | CA$5.28 Million | -20.92% |
| 2023-09-30 | CA$6.68 Million | +31.20% |
| 2022-09-30 | CA$5.09 Million | -22.26% |
| 2021-09-30 | CA$6.55 Million | +42.12% |
| 2020-09-30 | CA$4.61 Million | +32.85% |
| 2019-09-30 | CA$3.47 Million | +101.91% |
| 2018-09-30 | CA$1.72 Million | +172.19% |
| 2017-09-30 | CA$631.35K | +30.46% |
| 2016-09-30 | CA$483.94K | -4.74% |
| 2015-09-30 | CA$508.02K | +23.19% |
| 2014-09-30 | CA$412.38K | -10.78% |
| 2013-09-30 | CA$462.19K | +2.89% |
| 2012-09-30 | CA$449.23K | +13.15% |
| 2011-09-30 | CA$397.02K | +7.18% |
| 2010-09-30 | CA$370.41K | +6.58% |
| 2009-09-30 | CA$347.56K | -86.49% |
| 2008-09-30 | CA$2.57 Million | +30.33% |
| 2007-09-30 | CA$1.97 Million | +23.52% |
| 2006-09-30 | CA$1.60 Million | -21.86% |
| 2005-09-30 | CA$2.04 Million | +1.47% |
| 2004-09-30 | CA$2.02 Million | +28.74% |
| 2003-09-30 | CA$1.57 Million | +3619.39% |
| 2002-09-30 | CA$42.08K | -81.70% |
| 2001-09-30 | CA$229.99K | -28.18% |
| 2000-09-30 | CA$320.21K | +56.02% |
| 1999-09-30 | CA$205.23K | -35.03% |
| 1998-09-30 | CA$315.90K | -16.91% |
| 1997-09-30 | CA$380.18K | -- |
About Arch Biopartners Inc
Arch Biopartners Inc., together with its subsidiaries, engages in the development of novel drugs for acute kidney injury and organ damage in Canada. It focuses on developing its lead drug candidate LSALT Peptide, which is in Phase 2 trials to treat inflammation related acute kidney injury experienced by patients undergoing on-pump (bypass) cardiac surgery; and cilastatin to prevent toxin related … Read more